Detalhe da pesquisa
1.
Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of TP53 mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group.
Haematologica
; 2023 Nov 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38031755
2.
Diagnosis and prognosis are supported by integrated assessment of next-generation sequencing in chronic myeloid malignancies. A real-life study.
Haematologica
; 106(3): 701-707, 2021 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32241844
3.
A French multicentric prospective prognostic cohort with epidemiological, clinical, biological and treatment information to improve knowledge on lymphoma patients: study protocol of the "REal world dAta in LYmphoma and survival in adults" (REALYSA) cohort.
BMC Public Health
; 21(1): 432, 2021 03 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33653294
4.
A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma.
Haematologica
; 104(1): 138-146, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30171024
5.
Bendamustine and rituximab in elderly patients with low-tumour burden follicular lymphoma. Results of the LYSA phase II BRIEF study.
Br J Haematol
; 183(1): 76-86, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30117149
6.
Challenges for quality and utilization of real-world data for diffuse large B-cell lymphoma in REALYSA, a LYSA cohort.
Blood Adv
; 8(2): 296-308, 2024 01 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-37874913
7.
Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low-Tumor Burden Follicular Lymphoma: Results of a LYSA Study.
J Clin Oncol
; 41(19): 3523-3533, 2023 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37071836
8.
Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience.
Clin Cancer Res
; 28(23): 5211-5220, 2022 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36201165
9.
A phase I/II feasibility vaccine study by autologous leukemic apoptotic corpse-pulsed dendritic cells for elderly AML patients.
Hum Vaccin Immunother
; 17(10): 3511-3514, 2021 10 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34152898
10.
Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group.
Eur J Nucl Med Mol Imaging
; 37(9): 1633-42, 2010 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-20428863
11.
Efficient monocyte-derived dendritic cell generation in patients with acute myeloid leukemia after chemotherapy treatment: application to active immunotherapy.
Exp Hematol
; 36(3): 329-39, 2008 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-18207305
12.
Prospective evaluation of lymphoma response to immunomodulatory therapy criteria in GATA trial from the LYSA group.
Blood Adv
; 7(14): 3735-3738, 2023 07 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-37067945
13.
The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement.
Haematologica
; 92(10): 1335-42, 2007 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-18024371
14.
[Paclitaxel-induced lupus]. / Lupus induit par le paclitaxel.
Presse Med
; 36(9 Pt 1): 1207-8, 2007 Sep.
Artigo
em Francês
| MEDLINE | ID: mdl-17521858
15.
Consolidation anti-CD22 fractionated radioimmunotherapy with 90Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial.
Lancet Haematol
; 4(1): e35-e45, 2017 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-27964867
16.
Induction of leukemia-specific cytotoxic response by cross-presentation of late-apoptotic leukemic blasts by autologous dendritic cells of nonleukemic origin.
Cancer Res
; 62(10): 2861-8, 2002 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-12019165
17.
Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required.
Clin Infect Dis
; 40(4): e35-7, 2005 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-15712069
18.
Administration of mylotarg 4 days after beginning of a chemotherapy including intermediate-dose aracytin and mitoxantrone (MIDAM regimen) produces a high rate of complete hematologic remission in patients with CD33+ primary resistant or relapsed acute myeloid leukemia.
Leuk Res
; 29(9): 1003-7, 2005 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-16038726
19.
Patients with CD45 negative multiple myeloma receiving high-dose therapy have a shorter survival than those with CD45 positive multiple myeloma.
Haematologica
; 89(5): 547-51, 2004 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-15136217
20.
Disseminated mucormycosis associated with invasive pulmonary aspergillosis in a patient treated for post-transplant high-grade non-Hodgkin's lymphoma.
Leuk Lymphoma
; 45(10): 2161-3, 2004 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-15370266